Latus Bio Appoints Ainslie Little as COO and Katie as interim CBO
02 Jun 2025 //
BUSINESSWIRE
Latus Bio Publishes AAV Capsid Data for Neuro Gene Therapy
20 May 2025 //
BUSINESSWIRE
Latus Bio Reveals AAV-Ep+ Capsid Variant for Protein Production
14 May 2025 //
BUSINESSWIRE
Latus Bio to Present at American Society for Gene & Cell Therapy
29 Apr 2025 //
BUSINESSWIRE
Latus Bio Presents Data On Huntington’s Disease Gene Therapy
24 Feb 2025 //
BUSINESSWIRE
Pilatus Biosciences Secures FDA Orphan Drug Designation for PLT012
10 Dec 2024 //
PR NEWSWIRE
Latus Launches With $54M Series A, Gene Therapy Tech, Candidates
02 May 2024 //
BUSINESSWIRE